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Background: Severe left ventricular hypertrophy (LVH) has a well documented severe
negative impact on early mortality in patients undergoing surgical aortic valve replace-
ment. This effect is particularly pronounced in patients with elevated relative wall
thickness, an indicator of extreme hypertrophy with small ventricular cavity(suicide
ventricle). It is not clear whether similar mortality risk is present in transcatheter aortic
valve replacement(TAVR), which avoids issues regarding myocardial protection and
hyperdynamic post-bypass physiology. The purpose of this study is to analyze the impact
of LVH on patients undergoing TAVR.
Methods: From 2008-2011, a retrospective review of patients undergoing TAVR was
performed, comparing patients without severe LVH (n59) to those with severe LVH
(group 2, n89). LVH was defined as a relative wall thickness (2xPosterior wall
Thickness/LVEDD) of greater than 0.5. Data was abstracted from a prospectively kept
database with robust echocardiograhpic and clinical follow-up.
Results: Preoperative age, STS score, and aortic valve area did not differ (age: 81 vs. 84
years; STS score 12 vs. 12; AVA 0.61 vs. 0.61cm2, no LVH versus severe LVH groups
respectively). Peak gradient (PG) was higher in severe LVH group (PG 79 vs. 84mmHg,
p0.0001) but mean gradient (MG) did not differ (MG: 47 vs. 49mmHG, pNS). The
severe LVH group had a higher LV ejection fraction(p0.001), higher preoperative
pulmonary artery pressures(p0.001), worse mitral and tricuspid regurgitation(p0.01).
There was no difference in peri-procedural mortality (6.8% vs. 7.8%, p0.5). There were
not differences in ventilation time, inotrope use or overall length of stay between groups.
At 1 year follow up, mortality rates did not differ (29 vs. 25%, p0.3). PG and MG did
not differ (PG: 23 vs. 24mmH, MG: 12 vs. 12mmHg). LV mass regression did not differ
between groups. The severe LVH group continued to have a higher ejection fraction (59
vs. 67%, p0.001).
Conclusions: Unlike surgical AVR patients, the presence of severe left ventricular
hypertrophy in patients undergoing TAVR was not correlated with adverse outcomes at
1 year.
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Background: Transcatheter aortic valve implantation (TAVI) is increasingly gaining
ground as a treatment for high-risk patients with aortic stenosis. We evaluated the changes
in mitral valve regurgitation (MR) after TAVI with Medtronic CoreValve (MCV) or
Edwards Sapien XT (EXT).
Methods: We included 157 high-risk patients undergoing TAVI either with MCV
(n100) or EXT (n57). Mean age was 79.936.84 years and mean logEuroSCORE
was 23.3612.05%. All patients underwent transthoracic echo prior to TAVI and at
discharge and MR was evaluated based on the American Society of Echocardiography
classification (none, mild, moderate, severe).
Results: Procedural success was 100% for both valves (p0.40). Thirty-day mortality
was 2.0% for MCV and 1.7% for EXT. Figure 1 demonstrates the changes in MR in the
total cohort, and in patients with preserved ejection fraction (EF40%)(n134) and
impaired EF (40%)(n23). A trend for lower MR post-TAVI was observed in patients
with EF40% (p0.072), whereas no differences were evident in the group with
EF40% (p0.74). Specifically, in the group with EF40%, 12.7% of the patients
(n17) had a reduction in MR of at least 1 grade, while an increase of 1 grade in MR was
documented in 6% (n8). Finally, all 17 patients with preserved EF and MR reduction
had mild or moderate MR pre-TAVI, while all 8 patients with EF40%and MR increase
had no or mild MR pre-TAVI.
Conclusions: Our findings suggest that TAVI in patients with preserved EF could be
associated with improvement in preexisting MR, whereas there seems to be no such
benefit for patients with impaired EF.
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Background: The preoperative assessment of aortic annular dimensions and geometry is
essential for optimal TAVI type selection and sizing. Particularly in oval-shaped annuli,
multislice computed tomography (MSCT) has been shown to provide more accurate
aortic annular geometric sizing as compared with 2D TEE. Real-time 3D transesophageal
echocardiography (3D-TEE) imaging is gaining importance in both diagnostic evaluation
and periprocedural guidance during cardiac interventions. We evaluated whether 3D-TEE
can provide additional morpho-geometrical information for TAVI planning.
Methods: In 52 consecutive patients who underwent TAVI in our institution (57%
Medtronic CoreValve, 43% Edwards Sapien; EuroSCORE 26.3%, mean age 83.1 years),
analysis of all imaging data (2D- and 3D-TEE and MSCT) was performed retrospectively
by experienced physicians blinded to the valve type and size actually implanted. TAVI
prosthesis size had been chosen based on manufacturer’s recommendation and after
review of all available imaging modalities by our HeartTeam. Mean aortic annular
diameter (MAAD) was calculated from planimetric annular area in both MSCT and
3D-TEE datasets, and aortic annular diameter was additionally measured in the 2D-TEE
long axis view.
Results: In 8/52 patients (15.4%), MSCTs were acquired without contrast agent due to
severely impaired renal function. On average, 2D-TEE (22.32.6 mm) underestimated
MAAD by 0.5 mm as compared to 3D-TEE (22.82.0 mm) and by 1.3 mm as compared
to MSCT (23.62.2 mm). The valve size actually used was congruent with regard to
3D-TEE-measurements in 38/52 (73.1%), and with CT-measurements in 44/52 (84.6%)
of patients. Of those remaining 8 CT-examinations (6 acquired without contrast media),
MAAD for TAVI planning could be more reliably measured by 3D-TEE (7/8 patients)
than by 2D measurements alone, especially in cases of strongly asymmetric annulus
shape.
Conclusions: Echocardiography measures (2D and 3D) of the aortic annulus tend to be
smaller than MSCT analyses. 3D-TEE and MSCT show clear advantages for the
assessment of oval-shaped annuli. In cases with suboptimal MSCT-quality (15%) or
equivocal results of other imaging modalities, 3D-TEE imaging optimizes TAVI
planning.
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Background: We retrospectively evaluated the echocardiographic parameters for reverse
remodeling to predict 1year mortality in 50 patients (pts) enrolled in PARTNER trial at
single US center.
Methods: Baseline clinical, echocardiographic and procedural data was collected at
baseline, after the procedure in 1-7 days and at 6 months.
Results: Age was 858 years, NYHA 3.60.5, aortic valve area (AVA) 0.80.4, mean
AV pressure gradient (MPG) 4412, and LV ejection fraction (LVEF) 5515. At 6
months of after transcatheter aortic valve replacement (TAVR), 20 patients (40%)
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AM www.jacc.tctabstracts2012.com
B260 JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Aortic Valve Disease and TAVR
P
O
ST
E
R
S
